NVIV
$1.01
Invivo Therapeutics Holdings
($.10)
(9.01%)
NVIV
Earnings Whisper ®
N/A
Consensus: $0.00
Revenue: N/A
Thursday
Nov 5
After the close
Share
Watch
What do you expect when NVIV reports earnings?
Where is NVIV's stock price going from here?
Analysts
Pivots
Resistance
$1.16
$1.10
$1.06
Support
$0.95
$0.89
$0.84
Description
InVivo Therapeutics Holdings Corp. operates as a medical device company focused on utilizing polymers as a platform technology to develop treatments to improve function in individuals paralyzed as a result of traumatic spinal cord injury. The company intends to offer three products, including a biocompatible polymer scaffolding device to treat acute wound SCI; a biocompatible hydrogel for local controlled release of methylprednisolone to treat acute SCI; and a biocompatible polymer scaffolding device seeded with autologous hNSCs to treat acute and chronic SCI. InVivo Therapeutics Holdings Corp. is based in Cambridge, Massachusetts.